



## Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences

August 27, 2024

SAN DIEGO--(BUSINESS WIRE)--Aug. 27, 2024-- Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and addressing unmet medical needs within liver and respiratory rare diseases, today announced that the Company will participate in the following investor and scientific conferences:

### Wells Fargo 2024 Healthcare Conference (Fireside Chat)

- Wednesday, September 4, 2024 (3:00 p.m. ET)

### RNA Leaders USA Conference (Presentation)

- Thursday, September 5, 2024 (2:15 p.m. ET)

### H.C. Wainwright 26<sup>th</sup> Annual Global Investment Conference (Presentation)

- Monday, September 9, 2024 (11:00 a.m. ET)

### Cantor Fitzgerald Annual Healthcare Conference (Fireside Chat)

- Wednesday, September 18, 2024 (8:00 a.m. ET)

Webcast links can be found under Investor Relations/Events section of Arcturus' [website](#).

### About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed Kostaive®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus' pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit [www.ArcturusRx.com](http://www.ArcturusRx.com). In addition, please connect with us on [Twitter](#) and [LinkedIn](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240827510429/en/): <https://www.businesswire.com/news/home/20240827510429/en/>

### IR and Media Contacts

Arcturus Therapeutics  
Neda Safarzadeh  
VP, Head of IR/PR/Marketing  
(858) 900-2682  
[IR@ArcturusRx.com](mailto:IR@ArcturusRx.com)

Source: Arcturus Therapeutics Holdings Inc.